Finished product reference
Amlodipine / Bisoprolol Fumarate
Tablet · Oral · 5 mg/5 mg
- List code
- 52829
- Salt form
- Besilate
- Pharmacologic class
- Antihypertensive combination (dihydropyridine calcium-channel blocker + cardioselective beta-blocker)
What it is and how it works
Amlodipine blocks L-type calcium channels in vascular smooth muscle, causing arterial vasodilatation. Bisoprolol selectively blocks beta-1 adrenoceptors, reducing heart rate, cardiac output and renin release; the combination has complementary antihypertensive and antianginal effects.
Indications
Hypertension and/or stable angina in adults already controlled on amlodipine and bisoprolol given separately at the same doses.
Dosage and administration (summary)
One tablet orally once daily at the strength corresponding to the established individual doses (e.g. bisoprolol 5–10 mg with amlodipine 5–10 mg).
Contraindications
Acute or decompensated heart failure; cardiogenic shock; second- or third-degree AV block or sick sinus syndrome without pacemaker; symptomatic bradycardia or hypotension; severe asthma; severe aortic stenosis; severe peripheral arterial disease.
Warnings and precautions
Do not stop abruptly because of the risk of rebound angina. May mask hypoglycaemia and signs of thyrotoxicosis; caution in diabetes, COPD, psoriasis and hepatic impairment. Peripheral oedema is common with amlodipine.
Pregnancy
Not recommended in pregnancy unless clearly necessary; beta-blockers may cause fetal growth restriction and neonatal bradycardia or hypoglycaemia.
Storage and supply
Store below 30 °C, protected from light and moisture.
Source: reference summary prepared from the EU SmPC/EPAR, BNF and WHO Model Formulary. The approved product information in Iran governs.
Other presentations of the same active ingredient
Reference information for professional sourcing and registration enquiries, not medical advice or a promotion. Drug information is condensed from US FDA prescribing information (public domain, via openFDA and DailyMed) and does not replace the product’s approved labelling in Iran. Availability, origin and documentation are confirmed per enquiry.
Tell us the quantity, the market and the timing.
Send the molecule or ingredient, the specification and the destination. We reply from Tehran with the questions, the documents and the next step.